New NICE criteria for drug access

The new criteria, to be introduced by NICE and NHS England on April 1, 2017, could lead to England falling further behind other European countries in drug availability, endanger clinical trials, and jeopardise the industrial standing of life sciences post-Brexit. NICE has stated that “The changes ar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2017-05, Vol.18 (5), p.576-576
1. Verfasser:	Fricker, Janet
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Cancer therapies Clinical trials Cost-Benefit Analysis Drug Costs - legislation & jurisprudence Drug Industry - economics Drug Industry - legislation & jurisprudence Drugs England Government Regulation Health Policy - economics Health Policy - legislation & jurisprudence Health Services Accessibility - economics Health Services Accessibility - legislation & jurisprudence Hematology, Oncology and Palliative Medicine Humans Life sciences Patients Pharmaceutical industry Policy Making Prostate State Medicine - economics State Medicine - legislation & jurisprudence
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!